Biochem/physiol Actions

Cell permeable: no

Reversible: no

Primary TargetPromotes assembly of microtubules and inhibits tubulin disassembly.

Product does not compete with ATP.

General description

A semi-synthetically derived form of Paclitaxel (TAXOL^®, Cat. No. 580555) having no contamination of natural taxanes. Also has less epimerization products as contaminants. Promotes assembly of microtubules and inhibits tubulin disassembly. An effective agent in blocking HeLa and B16 cells at the G₂/M stage. Inhibits DNA synthesis and stimulates the release of tumor necrosis factor-α. Induces apoptosis in murine mammary carcinoma MCA-4 and ovarian carcinoma OCA-1 tumors.

A semi-synthetic form of Paclitaxel (Cat. No. 580555) having no contamination by natural taxanes. Also has reduced levels of epimerization products as contaminants.

Legal Information

Taxol is a registered trademark of Bristol-Myers Squibb Co.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Derry, W.B., et al. 1995. Biochemistry 34, 2203.Milas, L., et al. 1995. Cancer Chemother. Pharmacol.35, 297.Donaldson, K.L., et al. 1994. Int. J. Cancer 57, 847.Hornback, N.B., et al. 1994. In Vivo8, 819.Manthey, C.L., et al. 1992. J. Immunol. 149, 2459.Rowinsky, E.K., et al. 1992. Semin. Oncol.19, 646.Ding, A.H., et al. 1990. Science248, 370.Mogensen, M.M. and Tucker, J.B. 1990. J. Cell Sci.97, 101.Slichenmeyer, W.J. and Von Hoff, D.D. 1990. J. Clin. Pharmacol. 30, 770.

Packaging

5 mg in Plastic ampoule

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.

Warning

Toxicity: Carcinogenic / Teratogenic (D)